Next Article in Journal
Design, Synthesis and Activity of New Polymyxins
Previous Article in Journal
Lipid-Oligonucleotide Conjugates Forming G-Quadruplexes (Lipoquads) as Potent Inhibitors of HIV Entry
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Proceedings
Volume 1
Issue 6
10.3390/proceedings1060641
proceedings-logo
Submit to this Journal
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Abstract

Identification of a Novel Anti-Mycobacterial Series †

by
Esther Porras
* and
Carlos Alemparte
GSK, Tres Cantos 28760, Spain
*
Author to whom correspondence should be addressed.
†
Presented at the 1st Molecules Medicinal Chemistry Symposium, Barcelona, Spain, 8 September 2017.
Proceedings 2017, 1(6), 641; https://doi.org/10.3390/proceedings1060641
Published: 20 October 2017
(This article belongs to the Proceedings of Proceedings of the 1st Molecules Medicinal Chemistry Symposium, Barcelona, Spain)
Versions Notes
Tuberculosis (TB) is the biggest global killer in history. One of the main objectives for fighting TB is to find a shorter treatment and also to target multidrug-resistant (MDR) and extensively drug-resistant XDR strains. Nowadays, finding and developing new compounds that are active against tuberculosis constitutes a main objective for the Diseases of the Developing World (DDW) center of GlaxoSmithKline (GSK) at Tres Cantos. At our site, both target- and cell-based screens have been approached to identify new anti-TB compounds. Mtb phenotypic HTS represents the main source of new chemical entities, although the major challenge resides in their successful optimization and the elucidation of their mechanism of action (MoA).
In this work, we will present a new hit (GSK1) from a whole cell phenotypic screen and also Medicinal Chemistry efforts in the Hit Optimization program to overcome the risks associated with the Lead.

Acknowledgments

We would like to thank Wellcome Trust for the financial support.

Conflicts of Interest

The authors declare no conflict of interest.
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Porras, E.; Alemparte, C. Identification of a Novel Anti-Mycobacterial Series. Proceedings 2017, 1, 641. https://doi.org/10.3390/proceedings1060641

AMA Style

Porras E, Alemparte C. Identification of a Novel Anti-Mycobacterial Series. Proceedings. 2017; 1(6):641. https://doi.org/10.3390/proceedings1060641

Chicago/Turabian Style

Porras, Esther, and Carlos Alemparte. 2017. "Identification of a Novel Anti-Mycobacterial Series" Proceedings 1, no. 6: 641. https://doi.org/10.3390/proceedings1060641

APA Style

Porras, E., & Alemparte, C. (2017). Identification of a Novel Anti-Mycobacterial Series. Proceedings, 1(6), 641. https://doi.org/10.3390/proceedings1060641

Article Metrics

Back to TopTop